Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 132 of 144 pages ‹ First < 130 131 132 133 134 > Last ›
HSL2479
Collier J, Iheanacho I.
The pharmaceutical industry as an informant.
Lancet 2002 Nov 2; 360:(9343):1405-9
http://www.thelancet.com/journal/vol/iss/full/llan.360.9343.editorial_and_review.22976.1
HSL17887
James A.
Medicines, society, and industry.
Lancet 2002 Nov 2; 360:(9343):1346
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(02)11416-4
HSL17888
Ed.
An innovative challenge to the pharmaceutical industry
The Lancet 2002 Nov 2; 360:(9343):1341
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11417-6/fulltext
HSL17889
Hopkins Tanne J
Better standards needed for industry sponsored clinical trials
BMJ 2002 Nov 2; 325:(7371):985
http://www.bmj.com/cgi/content/extract/325/7371/985/a
HSL17890
Watson R
MEPs reject US-style direct advertising of drugs
BMJ 2002 Nov 2; 325:(7371):990
http://www.bmj.com/cgi/content/extract/325/7371/990/a
HSL2504
Drug companies offer DM programs for MS patients.
Dis Manag Advis. 2002 Nov 01; 8:(11):165-8, 161
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12506456
HSL414
Brodie M, Levitt L.
Drug advertising: the right or wrong prescription for our ailments?
Nat Rev Drug Discov 2002 Nov; 1:(11):916-20
http://www.nature.com/nrd/journal/v1/n11/abs/nrd943_fs.html;jsessionid=E0C11BC508A8240CE88E82D780D4A2C9
HSL1258
Wirth M, Scherer D.
Patient's perceptions of doctors' relationships with pharmaceutical companies
Healthy Skepticism International News 2002 Nov; 20:(11):
www.healthyskepticism.org
HSL1966
Rakatansky H.
Review article: gastroenterology and the pharmaceutical industry.
Aliment Pharmacol Ther 2002 Nov; 16:(11):1859-66
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2036.2002.01362.x
HSL2464
Glasgow C, Schommer JC, Gupta K, Pierson K.
Promotion of prescription drugs to consumers: case study results.
J Manag Care Pharm 2002 Nov-Dec; 8:(6):512-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14613384
HSL2492
Boltri JM, Gordon ER, Vogel RL.
Effect of antihypertensive samples on physician prescribing patterns.
Fam Med 2002 Nov-Dec; 34:(10):729-31
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12448641
HSL10621
Macia MA, Carvajal A, del Pozo JG, Vera E, del Pino A.
Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System.
Clin Pharmacol Ther 2002 Nov; 72:(5):596-7
HSL10662
Biswas PN, Wilton LV, Shakir SW.
The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
J Hum Hypertens 2002 Nov; 16:(11):795-803
http://www.nature.com/jhh/journal/v16/n11/abs/1001490a.html
HSL10663
Shiffman S, Gorsline J, Gorodetzky CW.
Efficacy of over-the-counter nicotine patch.
Nicotine Tob Res 2002 Nov; 4:(4):477-83
http://www.informaworld.com/smpp/content?content=10.1080/1462220021000018416
HSL10668
Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G.
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Eur J Clin Pharmacol 2002 Nov; 58:(8):495-500
http://www.springerlink.com/content/c52uy58a4h0jd0k2/
HSL16744
Lurie P, Wolfe SM.
Continuing exposure to hexavalent chromium, a known lung carcinogen: an analysis of OSHA compliance inspections, 1990-2000.
Am J Ind Med 2002 Nov; 42:(5):378-83
http://www3.interscience.wiley.com/journal/99017825/abstract?CRETRY=1&SRETRY=0
HSL17886
Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ.
Reported adverse drug events in infants and children under 2 years of age.
Pediatrics 2002 Nov; 110:(5):e53
http://pediatrics.aappublications.org/cgi/content/full/110/5/e53
HSL20270
Croskerry P
Achieving quality in clinical decision making: cognitive strategies and detection of bias
Acad Emerg Med 2002 Nov; 9:(11):1184-204
http://www.ncbi.nlm.nih.gov/pubmed/12414468
HSL17892
Steinbrook R.
Testing medications in children.
N Engl J Med 2002 Oct 31; 347:(18):1462-70
http://content.nejm.org/cgi/content/extract/347/18/1462
HSL17891
Ed.
Drug marketing: unsafe at any dose?
CMAJ 2002 Oct 29; 167:(9):981,
http://www.cmaj.ca/cgi/content/full/167/9/981
HSL2477
Corbett J.
Drug pushers - the campaign for Glivec funding
New Zealand Herald 2002 Oct 26
http://www.nzherald.co.nz/storydisplay.cfm?storyID=3001076
HSL17379
Milloy S
Beware Drug Company Marketing
FOX News 2002 Oct 25
http://www.foxnews.com/story/0,2933,66645,00.html
HSL1959
Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM.
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.
N Engl J Med 2002 Oct 24; 347:(17):1335-41
http://content.nejm.org/cgi/content/abstract/347/17/1335
HSL17893
Moses H 3rd, Braunwald E, Martin JB, Thier SO.
Collaborating with industry--choices for the academic medical center.
N Engl J Med 2002 Oct 24; 347:(17):1371-5
http://content.nejm.org/cgi/content/extract/347/17/1371
HSL17894
Benson J, Britten N
Patients' decisions about whether or not to take antihypertensive drugs: qualitative study
BMJ 2002 Oct 19; 325:(7369):873
http://www.bmj.com/cgi/content/abstract/325/7369/873
HSL17895
Patients make balanced decisions whether to take drugs
BMJ 2002 Oct 19; 325:(7369):
http://www.bmj.com/cgi/content/full/325/7369/0/b
HSL1994
O'Meara K P
Medical Research To Die For
Insight magazine 2002 Oct 15
HSL17896
Marwick C
US tackles drug company gifts to doctors
BMJ 2002 Oct 12; 325:(7368):795
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1169556/
HSL19958
Baker D, Chatani N
Promoting Good Ideas on Drugs: Are Patents the Best Way?
cepr 2002 Oct 11
http://www.cepr.net/index.php/publications/reports/promoting-good-ideas-on-drugs-are-patents-the-best-way/
HSL17395
Barclay L
OIG Guidelines: An Expert Interview With Arthur Palamara, MD
Medscape Medical News 2002 Oct 9
HSL17898
Joyce GF, Escarce JJ, Solomon MD, Goldman DP.
Employer drug benefit plans and spending on prescription drugs.
JAMA 2002 Oct 9; 288:(14):1733-9
http://jama.ama-assn.org/cgi/content/full/288/14/1733
HSL1992
Seglin J.
Just Saying No to Gifts From Drug Makers
The New York Times 2002 Oct 8
HSL1928
Sweet M.
Conference promotion in the media: serving whose interests?
Med J Aust 2002 Oct 7; 177:(7):341-2
http://www.mja.com.au/public/issues/177_07_071002/swe10463_fm.html
HSL1990
Moore K.
Drug companies push pills to doctors
Morning Journal Writers 2002 Oct 7
HSL1998
Croasdale M.
CME providers gear up to comply with PhRMA code: Eager to follow new guidelines separating drug promotions from continuing medical education, CME presenters' questions outpace answers at a meeting of drug industry and education leaders.
AMNews 2002 Oct 7
HSL17897
Kapp C.
Counterfeit drug problem
Lancet 2002 Oct 5; 360:(9339):1080
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11185-8/fulltext
HSL1196
Braithwaite J.
Restorative Justice and Responsive Regulation
Oxford: Oxford University Press 2002
http://www.oup.co.uk/isbn/0-19-515839-3
HSL2307
Cassels A.
Consumer drug advertising leads to MD backlash in Holland.
CMAJ 2002 Oct 1; 167:(7):793
http://www.cmaj.ca/cgi/content/full/167/7/793
HSL5322
Coast J, Smith R, Karcher AM, Wilton P, Millar M.
Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?
Health Econ 2002 Oct 01; 11:(7):637-47
http://www3.interscience.wiley.com/cgi-bin/abstract/93521364/ABSTRACT
HSL19522
Pear R
Drug Industry Is Told to Stop Gifts to Doctors
The New York Times 2002 Oct 1
http://www.nytimes.com/2002/10/01/national/01DRUG.html
HSL1419
Jureidini J.
Does the International Consensus Statement on ADHD leave room for healthy scepticism?
Eur Child Adolesc Psychiatry 2002 Oct; 11:(5):240
HSL1893
Brotons C, Moral I, Ribera A, Cascant P, Iglesias M, Permanyer-Miralda G, Ferreira Gonzalez I, Soler-Soler J.
[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention.]
Rev Esp Cardiol 2002 Oct; 55:(10):1042-51
http://www.revespcardiol.org/cgi-bin/wdbcgi.exe/cardio/cardioeng.acceso_full.alta
HSL2201
Maitland I.
Priceless goods: how should life-saving drugs be priced?
Bus Ethics Q 2002 Oct; 12:(4):451-80
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12708456
HSL10432
New drugs: watch out for unexpected adverse effects.
Prescrire Int. 2002 Oct; 11:(61):150-1
http://www.ncbi.nlm.nih.gov/pubmed/12378747
HSL2449
Transparency International.
Slovak judge, German pharmacologist and Brazilian campaigner win anti-corruption award
2002 Sep 30;
http://www.transparency.org/pressreleases_archive/2002/2002.09.30.anti_corruption_award.html
HSL2082
Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B.
Discontinuation of use and switching of antidepressants: influence of patient-physician communication.
JAMA 2002 Sep 18; 288:(11):1403-9
http://jama.ama-assn.org/cgi/content/full/288/11/1403
HSL19523
Petersen M.
Pediatric book on breast-feeding stirs controversy
The New York Times 2002 Sep 18
http://www.nytimes.com/2002/09/18/business/media/18ADCO.html
HSL1690
Shear NH.
Principles of influence.
CMAJ 2002 Sep 17; 167:(6):628
http://www.cmaj.ca/cgi/content/full/167/6/628
HSL17378
Marbin Miller C
Mind-altering drugs given to some babies in DCF's care
Miami Herald 2002 Sep 17
HSL1993
Adams C.
Firms Pressure FDA to Relax Rules on Commercial Speech
The Wall Street Journal 2002 Sep 17
http://online.wsj.com/article/SB1032211864319468275.html?mod=googlewsj
HSL1808
Salleh A.
Prescription drug ads under attack
ABC Science Online 2002 Sep 16
http://www.abc.net.au/science/articles/2002/09/16/675698.htm
HSL1975
Newby DA, Henry DA.
Drug advertising: truths, half-truths and few statistics.
Med J Aust 2002 Sep 16; 177:(6):285-6
http://www.mja.com.au/public/issues/177_06_160902/new10443_fm.html
HSL2243
Loke TW, Koh FC, Ward JE.
Pharmaceutical advertisement claims in Australian medical publications.
Med J Aust 2002 Sep 16; 177:(6):291-3
http://www.mja.com.au/public/issues/177_06_160902/lok10004_fm.html
HSL1979
Moynihan R.
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
BMJ 2002 Sep 14; 325:(7364):592-5
http://bmj.bmjjournals.com/cgi/content/full/325/7364/592
HSL17899
Lièvre M
Alosetron for irritable bowel syndrome
BMJ 2002 Sep 14; 325:(7364):555–556
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124090/
HSL17900
Jackson T
Press: Both sides now
BMJ 2002 Sep 14; 325:(7364):603
http://www.bmj.com/cgi/content/full/325/7364/603/a
HSL1809
Burson-Marsteller's Task Force
Media Watch. Australian Broadcasting Commission 2002 Sep 13
www.abc.net.au/mediawatch/transcripts/300902_s3.htm
HSL5423
Accreditation Council for Graduate Medical Education
Principles to Guide the Relationship between Graduate Medical Education and Industry
: Accreditation Council for Graduate Medical Education 2002 Sep 10
http://www.acgme.org/acWebsite/positionPapers/pp_GMEGuide.pdf
HSL2004
Wysong P.
Time with drug reps affects prescribing: study
The Medical Post. 2002 Sep 8
HSL2482
Clifford TJ, Barrowman NJ, Moher D.
Funding source, trial outcome and reporting quality: are they related? Results of a pilot study
BMC Health Serv Res 2002 September 4; 2:(1):18
http://www.biomedcentral.com/1472-6963/2/18
HSL7674
McAllister JC 3rd.
Providing for the pharmaceutically indigent.
Am J Health Syst Pharm 2002 Sep 1; 59:(17):1678-9
http://www.ajhp.org/cgi/reprint/59/17/1678
HSL8945
Cox TP.
Forging Alliances: Advocacy Partners
Pharmaceutical Executive 2002 Sep 1
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=29974
HSL1259
Wazana A, Primeau F.
Ethical considerations in the relationship between physicians and the pharmaceutical industry.
Psychiatr Clin North Am 2002 Sep; 25:(3):647-63,
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12232977
HSL1611
Sagarin BJ, Cialdini RB, Rice WE, Serna SB.
Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion.
J Pers Soc Psychol 2002 Sep; 83:(3):526-41
http://content.apa.org/journals/psp/83/3/526
HSL1917
Wall LL, Brown D.
Pharmaceutical sales representatives and the doctor/patient relationship.
Obstet Gynecol 2002 Sep; 100:(3):594-9
http://www.greenjournal.org/cgi/content/full/100/3/594
HSL1932
Stewart KA, Neumann PJ.
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Value Health 2002 Sep-Oct; 5:(5):389-96
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12201856
HSL1961
Safer DJ.
Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
J Nerv Ment Dis 2002 Sep; 190:(9):583-92
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0022-3018&volume=190&issue=9&spage=583
HSL1976
Neumann PJ, Zivin Bambauer K, Ramakrishnan V, Stewart KA, Bell CM.
Economic messages in prescription drug advertisements in medical journals.
Med Care 2002 Sep; 40:(9):840-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12218774
HSL1981
Motola G, Mazzeo F, Rinaldi B, Capuano A, Rossi S, Russo F, Vitelli MR, Rossi F, Filippelli A.
Self-prescribed laxative use: a drug-utilization review.
Adv Ther 2002 Sep-Oct; 19:(5):203-8
https://www.advancesintherapy.com/frame.asp?https://www.advancesintherapy.com/detail.aspx?ID=272
HSL2088
Fugh-Berman A, Pearson C.
The overselling of hormone replacement therapy.
Pharmacotherapy 2002 Sep; 22:(9):1205-8
HSL2136
Caamano F, Figueiras A , Gestal-Otero JJ.
Influence of commercial information on prescription quantity in primary care.
Eur J Public Health 2002 Sep; 12:(3):187-91
http://eurpub.oxfordjournals.org/cgi/reprint/12/3/187?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Caamano%2C+F&andorexactfulltext=and&searchid=1124411285121_316&stored_search=&FIRSTINDEX=0&sortspec=relevance&resourcetype=1&journalcode=eurpub
HSL2476
Cox ER, Henderson RR.
Prescription use behavior among medicare beneficiaries with capped prescription benefits.
J Manag Care Pharm 2002 Sep-Oct; 8:(5):360-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14613402
HSL7658
De Las Cuevas C, Sanz EJ, De La Fuente JA.
Variations in antidepressant prescribing practice: clinical need or market influences?
Pharmacoepidemiol Drug Saf 2002 Sep; 11:(6):515-22
HSL10629
Bachert C, El-Akkad T.
Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.
Ann Allergy Asthma Immunol 2002 Sep; 89:(3):292-7
HSL12519
Le TV.
Money talks
Reportage 2002 Sep
http://www.reportage.uts.edu.au/stories/2002/media/pr2k9.html
HSL1807
Company News; Glaxo Seeks F.D.A. Approval Of Depression Treatment
2002 Aug 30
HSL2451
Health ACTION.
European Parliament soundly rejects move towards direct-to-consumer advertising. HAI Europe applauds Parliament's decision to protect public health, not industry's interests
2002 Aug 24;
http://www.haiweb.org/campaign/DTCA/pressreleaseEUrejectsDTCA.html
HSL2079
Sackett DL.
The arrogance of preventive medicine.
CMAJ 2002 Aug 20; 167:(4):363-4
http://www.cmaj.ca/cgi/content/full/167/4/363
HSL2308
Sheldon T.
Dutch GPs call for ban on Novartis products.
BMJ 2002 Aug 17; 325:(7360):355
http://bmj.bmjjournals.com/cgi/content/full/325/7360/355
HSL19860
Hansen J, Farrow N
Doctoring the Spin
Sunday 2002 Aug 16
http://sgp1.paddington.ninemsn.com.au/sunday/cover_stories/transcript_1121.asp
HSL1991
Philip Morris Muzzled Marketing of Cessation Products
Join Together 2002 Aug 15
http://www.jointogether.org/news/headlines/inthenews/2002/philip-morris-muzzled-of.html
HSL1929
Sweet M.
Australian media raises alarm over meningitis
BMJ 2002 Aug 14; 325:604
http://bmj.com/cgi/content/full/325/7364/604
HSL1958
Shamasunder B, Bero L.
Financial ties and conflicts of interest between pharmaceutical and tobacco companies.
JAMA 2002 Aug 14; 288:(6):738-44
http://jama.ama-assn.org/cgi/content/full/288/6/738
HSL2466
Fontanarosa PB, DeAngelis CD.
The importance of the journal embargo.
JAMA 2002 Aug 14; 288:(6):748-50
http://jama.ama-assn.org/cgi/content/full/288/6/748
HSL1806
Petersen M.
Heartfelt Advice, Hefty Fees
New York Times 2002 Aug 11
http://www.nytimes.com/2002/08/11/business/heartfelt-advice-hefty-fees.html?pagewanted=1
HSL68
Gerstel J.
Who benefits when doctors endorse drugs?
The Tortonto Star 2002 Aug 9
HSL17392
Vogin GD
PhRMA Adopts New Marketing Code
Medscape Medical News 2002 Aug 9
http://www.medscape.com/viewarticle/439960
HSL17394
Vogin GD
PhRMA Code: A Newsmaker Interview with John T. Kelly, MD, PhD
Medscape Medical News 2002 Aug 9
HSL2253
Kjaergard LL, Als-Nielsen B.
Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.
BMJ 2002 Aug 3; 325:(7358):249
http://bmj.com/cgi/content/full/325/7358/249
HSL17377
Society of General Internal Medicine
Policy on Acceptance and Disclosure of External Funds
Society of General Internal Medicine 2002 Aug 2
HSL1892
Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, Dubois S, Russo R.
Assessing the quality of drug detailing.
J Clin Epidemiol 2002 Aug; 55:(8):825-32
HSL2505
[No authors listed].
Is Yasmin a 'truly different' drug?
Drug Ther Bull 2002 Aug; 40:(8):57-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12216337
HSL17376
Koerner BI
First, you market the disease... then you push the pills to treat it
The Guardian 2002 July 30
http://www.guardian.co.uk/news/2002/jul/30/medicineandhealth
HSL1775
Williams A.
The mental health industry
2002 Jul 16
HSL13260
Antonuccio DO, Burns DD, Danton WG.
Antidepressants: A triumph of marketing over science?
Prevention & Treatment. 2002 Jul 15; 5:(1):Item 25
http://content.apa.org/journals/pre/5/1/25
HSL14781
Fuller Torrey E.
The Going Rate on Shrinks
The American Prospect 2002 Jul 14
http://www.prospect.org/cs/articles?article=the_going_rate_on_shrinks
HSL20557
Moynihan R
Under the microscope
The Australian Financial Review 2002 July 1280
http://www.accessmylibrary.com/coms2/summary_0286-25921057_ITM
HSL2481
CMAJ
The invisible hand of the marketing department.
CMAJ 2002 Jul 9; 167:(1):5
http://www.cmaj.ca/cgi/content/full/167/1/5
HSL1772
Doctors under fire over drug company payments
2002 Jul 5
HSL1962
Rosack J.
Drug industry responds to complaints about marketing
Psychiatric News 2002 Jul 5; 37:(13):1
http://pn.psychiatryonline.org/cgi/content/full/37/13/1
Page 132 of 144 pages ‹ First < 130 131 132 133 134 > Last ›
